NCT00006379View on ClinicalTrials.gov

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

January 31, 2004

Study Completion Date

October 31, 2011

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesPrecancerous/Nonmalignant ConditionSmall Intestine Cancer
Interventions
BIOLOGICAL

anti-thymocyte globulin

anti-thymocyte globulin IV over at least 4 hours on days -2 and -1

BIOLOGICAL

graft-versus-tumor induction therapy

Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

DRUG

cyclophosphamide

cyclophosphamide IV over 2 hours on days -3 to -2

DRUG

fludarabine phosphate

fludarabine IV over 30 minutes on days -8 to -4

PROCEDURE

peripheral blood stem cell transplantation

Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Trial Locations (1)

44106-5065

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Case Comprehensive Cancer Center

OTHER

NCT00006379 - Non-Ablative Allo HSCT For Hematologic Malignancies or SAA | Biotech Hunter | Biotech Hunter